Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TESTOSTERONE CYPIONATE vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Male hypogonadism (primary or hypogonadotropic),Delayed puberty in males,Off-label: Female-to-male gender affirmation therapy, anemia of renal failure (historically)
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Primarily hepatic via CYP3A4 and CYP2B6; metabolites include androsterone and etiocholanolone; excreted in urine.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
97-99% bound to sex hormone-binding globulin (SHBG) and albumin
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.6-1.0 L/kg (reflects extensive distribution into tissues, including muscle and fat; total Vd ~4-9 L in adults)
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Intramuscular: 100% (administered as a depot injection in oil; undergoes first-pass metabolism if oral, but not relevant for IM route)
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
No specific dose adjustment recommended; however, monitor fluid retention and hypertension in patients with severe renal impairment (GFR <30 m L/min).
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
Child-Pugh A/B: No adjustment; Child-Pugh C: Contraindicated due to risk of hepatotoxicity.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Not recommended for use in pediatric patients for hypogonadism; for delayed puberty, IM testosterone cypionate 50 mg every 4 weeks initially, titrating upward as needed.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Start at lower end of dosing range (e.g., 50-100 mg every 2-4 weeks) due to increased risk of prostate enlargement and cardiovascular events; monitor serum testosterone levels and adjust accordingly.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
Prolonged use of high doses of testosterone has been associated with an increased risk of hepatocellular carcinoma.
None
Risk of polycythemia (monitor hematocrit), edema in patients with cardiac/renal/hepatic disease, accelerated growth in prepubertal males (monitor bone age), gynecomastia, sleep apnea exacerbation, prostate hyperplasia/carcinoma (monitor PSA), decreased spermatogenesis, elevated blood pressure, hyperlipidemia.
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Known or suspected prostate carcinoma, male breast carcinoma, pregnancy, hypersensitivity to testosterone cypionate, severe hepatic/renal/cardiac disease (relative), hypercalcemia (in patients with immobility).
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
No significant food interactions. Limit alcohol consumption as it may increase risk of liver damage. Grapefruit juice may interfere with testosterone metabolism; avoid excessive intake.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and third trimester exposure can also cause virilization. No adequate studies exist; use only if clearly needed for maternal condition, though use in pregnancy is generally avoided.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Testosterone is excreted into breast milk in low concentrations; M/P ratio not reported. Theoretical risk of androgenic effects in male infants (e.g., masculinization). Use with caution only if maternal benefit outweighs potential risk. Consider alternative therapies while breastfeeding.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
No specific dose adjustment studies exist. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) may reduce efficacy, but use of testosterone cypionate during pregnancy is contraindicated. If essential, dose may need titration to maintain desired androgen levels; however, risk outweighs benefit.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
Testosterone cypionate is a long-acting injectable androgen. Monitor hematocrit and hemoglobin due to risk of polycythemia. Use with caution in patients with sleep apnea, benign prostatic hyperplasia, or cardiovascular disease. Check serum testosterone levels 1 week after injection to assess adequacy. For men with hypogonadism, avoid in those with untreated hyperprolactinemia or pituitary tumor.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Inject deeply into the muscle (gluteal or thigh) to reduce pain and risk of abscess.,Do not use if you have breast cancer, prostate cancer, or are pregnant.,Report swelling in ankles, difficulty breathing, or severe headache immediately.,Do not take with blood thinners like warfarin without consulting your doctor.,Expect possible mood changes, increased acne, or hair loss. Monitor for priapism.,Regular blood tests are required to check red blood cell count, liver function, and prostate health.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
"Chlorpropamide, a sulfonylurea antidiabetic agent, stimulates pancreatic insulin secretion, while testosterone may enhance insulin sensitivity and reduce blood glucose levels. Concurrent use can lead to additive hypoglycemic effects, increasing the risk of hypoglycemia, particularly in patients with diabetes. This interaction is of clinical concern as it may necessitate dose adjustments of chlorpropamide to prevent hypoglycemic episodes."
"Flunisolide, a corticosteroid with mineralocorticoid activity, can potentiate the sodium- and water-retaining effects of testosterone, leading to an increased risk of edema, hypertension, and exacerbation of heart failure. This interaction is particularly significant in patients with pre-existing cardiovascular conditions, as the combined effects on fluid balance may require dose adjustments or closer monitoring."
"Fluorometholone, a corticosteroid with mineralocorticoid activity, may enhance sodium and water retention induced by testosterone, particularly in patients with pre-existing cardiac or renal conditions. This interaction can lead to increased fluid retention, exacerbation of hypertension, and potential precipitation of congestive heart failure. The risk is greater with high doses or prolonged use of either agent."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TESTOSTERONE CYPIONATE vs ANDROID 10, answered by our medical review team.
TESTOSTERONE CYPIONATE is a Androgen that works by Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TESTOSTERONE CYPIONATE and ANDROID 10 depend on the specific clinical indication. These are both Androgen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TESTOSTERONE CYPIONATE is: Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TESTOSTERONE CYPIONATE and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TESTOSTERONE CYPIONATE is classified as Category D/X. Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and thir. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.